Literature DB >> 3143557

Ro 15-1788-induced seizures in rats continually exposed to diazepam for prolonged periods.

M A Wilson1, D W Gallager.   

Abstract

Previous reports using rats have failed to demonstrate convulsions upon withdrawal from chronic benzodiazepine (BZ) treatment. We have shown earlier that rats develop tolerance to benzodiazepines following continuous exposure to low levels of diazepam (DZ) obtained by treatment with s.c. diazepam-filled silastic capsules. This report shows that intravenous infusion of the benzodiazepine antagonist Ro 15-1788 can induce seizures in rats treated for prolonged periods (4 weeks) with such diazepam-filled capsules. Precipitated seizures are also seen in rats 24 h after the cessation of chronic diazepam exposure. This procedure may provide a useful paradigm with which to study in rats the neural changes which are related to the physical dependence and withdrawal associated with prolonged exposure to the benzodiazepines.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3143557     DOI: 10.1016/0920-1211(88)90004-6

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  3 in total

1.  Physical dependence on diazepam in the dog: precipitation of different abstinence syndromes by the benzodiazepine receptor antagonists Ro 15-1788 and ZK 93426.

Authors:  W Löscher; D Hönack; C P Fassbender
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

2.  Withdrawal precipitation by benzodiazepine receptor antagonists in dogs chronically treated with diazepam or the novel anxiolytic and anticonvulsant beta-carboline abecarnil.

Authors:  W Löscher; D Hönack
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-04       Impact factor: 3.000

3.  Flumazenil-precipitated withdrawal in healthy volunteers following repeated diazepam exposure.

Authors:  Miriam Z Mintzer; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2004-09-25       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.